TH — Theratechnologies Share News
0.000.00%
Last trade - 00:00- CA$205.53m
- CA$252.52m
- $85.87m
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process
Brief: Soleus Capital Issues Letter To The Board Of Theratechnologies
Brief: Future Pak Submits Proposals To Acquire Theratechnologies., Offering Up To $255 Mln In Total Value
Corrected: BRIEF-Theratechnologies Q1 Revenue USD 19.05 Million
Brief: Theratechnologies Receives FDA Approval Of Prior Approval Supplement (Pas) For Egrifta Sv® Sbla
Theratechnologies gets FDA nod for new treatment of abdominal fat in HIV patients, shares soar
Brief: Theratechnologies Receives FDA Approval For EGRIFTA WR (Tesamorelin F8) To Treat Excess Visceral Abdominal Fat In Adults With HIV And Lipodystrophy
Brief: Theratechnologies Says It Resumes Distribution Of EGRIFTA SV®
Brief: Theratechnologies Announces Filing Of FDA Prior Approval Supplement For EGRIFTA SV Manufacturing Environment
Brief: Theratechnologies Gets March 2025 PDUFA Goal Date For Updated Tesamorelin F8 Formulation Sbla
Brief: Theratechnologies Announces Preliminary Tolerability And Efficacy Data From Phase 1B, Dose-Ranging Trial Of Sudocetaxel Zendusortide In Patients With Advanced Ovarian Cancer
Brief: Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
Brief: Theratechnologies Announces Resumed Production Of Egrifta Sv®
Brief: Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
Brief: Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
Brief: Theratechnologies Announces A Risk Of A Temporary Supply Disruption For Egrifta Sv In Early 2025